Search research articles
Contact Us
Filters
Showing results (791-800 of 814) with videos related to
Page
of 82
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 20, 1998
Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group
W Hiddemann, M Unterhalt, R Herrmann, et al.
Cancer
|
August 27, 2019
Standardized activities for lay patient navigators in breast cancer care: Recommendations from a citywide implementation study
Karen M Freund, Jennifer S Haas, Stephenie C Lemon, et al.
Leukemia
|
May 1, 1996
Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group
M Unterhalt, R Herrmann, M Tiemann, et al.
Journal of Cancer Research and Clinical Oncology
|
January 13, 2006
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)
W Pönisch, P S Mitrou, K Merkle, et al.
British Journal of Haematology
|
September 1, 2001
Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group
M Hallek, B Schmitt, M Wilhelm, et al.
JCI Insight
|
June 12, 2019
Targetable mechanisms driving immunoevasion of persistent senescent cells link chemotherapy-resistant cancer to aging
Denise P Muñoz, Steven M Yannone, Anneleen Daemen, et al.
Journal of Chromatography. A
|
August 22, 2015
Retention projection enables accurate calculation of liquid chromatographic retention times across labs and methods
Daniel Abate-Pella, Dana M Freund, Yan Ma, et al.
Journal of Biomedical Materials Research. Part A
|
July 23, 2013
Polypropylene surgical mesh coated with extracellular matrix mitigates the host foreign body response
Matthew T Wolf, Christopher A Carruthers, Christopher L Dearth, et al.
Journal of Cancer Research and Clinical Oncology
|
August 10, 2005
Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19)
M Herold, A Schulze, D Niederwieser, et al.
Bone Marrow Transplantation
|
February 21, 2007
Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma
M Schmidt-Hieber, I W Blau, R Trenschel, et al.
Page
of 82
Search research articles
Search
Showing results (791-800 of 814) with videos related to
Sort By:
Page
of 82
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 20, 1998
Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group
W Hiddemann, M Unterhalt, R Herrmann, et al.
Cancer
|
August 27, 2019
Standardized activities for lay patient navigators in breast cancer care: Recommendations from a citywide implementation study
Karen M Freund, Jennifer S Haas, Stephenie C Lemon, et al.
Leukemia
|
May 1, 1996
Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group
M Unterhalt, R Herrmann, M Tiemann, et al.
Journal of Cancer Research and Clinical Oncology
|
January 13, 2006
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)
W Pönisch, P S Mitrou, K Merkle, et al.
British Journal of Haematology
|
September 1, 2001
Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group
M Hallek, B Schmitt, M Wilhelm, et al.
JCI Insight
|
June 12, 2019
Targetable mechanisms driving immunoevasion of persistent senescent cells link chemotherapy-resistant cancer to aging
Denise P Muñoz, Steven M Yannone, Anneleen Daemen, et al.
Journal of Chromatography. A
|
August 22, 2015
Retention projection enables accurate calculation of liquid chromatographic retention times across labs and methods
Daniel Abate-Pella, Dana M Freund, Yan Ma, et al.
Journal of Biomedical Materials Research. Part A
|
July 23, 2013
Polypropylene surgical mesh coated with extracellular matrix mitigates the host foreign body response
Matthew T Wolf, Christopher A Carruthers, Christopher L Dearth, et al.
Journal of Cancer Research and Clinical Oncology
|
August 10, 2005
Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19)
M Herold, A Schulze, D Niederwieser, et al.
Bone Marrow Transplantation
|
February 21, 2007
Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma
M Schmidt-Hieber, I W Blau, R Trenschel, et al.
Page
of 82